CLAIMS

1. A compound of formula (I):



(I)

where X is N or CH;

A represents a group of formula (a) or (b)



(a)



(b)

R_1 represents a hydrogen atom or an $-NH_2$, $-NR_3R_4$, $-NR_3CO(C_1-C_4)Alk$ or $-NR_3SO_2(C_1-C_4)Alk$ group;

R_2 represents a hydrogen or halogen atom or a $(C_1-C_4)Alk$, (C_1-C_4)alkoxy, $-COOH$, $-COO(C_1-C_4)Alk$, $-CN$, $-CONR_3R_4$, $-NO_2$, $-SO_2NR_3R_4$ or $-NHSO_2(C_1-C_4)Alk$ group;

m and n each represent 0, 1 or 2;

R_3 and R_4 each represent a hydrogen atom or a $(C_1-C_4)Alk$ group;

Y_1 and Y_2 each represent NH or O;

and their salts or solvates.

2. The compound as claimed in claim 1, where X represents CH.

3. The compound as claimed in claim 1, where X represents a nitrogen atom and the R_2 group is in the 5-position.

4. The compound as claimed in claim 1, where the (C_1-C_4)Alk group is a methyl or ethyl group.

5. The compound as claimed in claim 1, where R_2 is chosen from -COOH, $-COO(C_1-C_4)Alk$, -CN, $-NO_2$, $-CONR_3R_4$ and $-NHSO_2-(C_1-C_4)Alk$.

6. 3-[1-(5-Ethoxycarbonylpyrid-2-yl)-4-piperidinylamino]-1-(1,2-dihydro-2-oxobenzimidazol-4-yloxy)-2-propanol and its salts or solvates.

7. 3-[1-(5-Ethoxycarbonylpyrid-2-yl)-4-piperidinylamino]-1-[2-aminopyrid-5-yloxy]-2-propanol and its salts or solvates.

8. A process for the preparation of the compound of claim 1, characterized in that an epoxide of formula (II):



(II)

in which A' represents the group (a) or the group (b) in which R_1 is optionally protected, where (a), (b) and R_1 are as defined in claim 1, is reacted with an amine of formula (III)



(III)

where m, n, R_2 and X are as indicated above, the protective group optionally present is removed and, optionally, the product of formula (I) thus obtained is converted into one of its salts or solvates.

9. A process for the preparation of the compound of claim 1 where A represents a group (b) and R_1 is an NH_2 group, characterized in that a product of formula (II) as defined in claim 8 where A' is the group (b) and R_1 is a group of formula:



is reacted with an amine of formula III and the product of formula IV thus obtained:



(IV)

is subjected to a hydrogenation reaction in order to

convert the 4-nitrophenyldiazenyl group to an amino group and, optionally, the product of formula (I) thus obtained is converted into one of its salts or solvates.

10. A process for the preparation of the compound of claim 1 where A represents the group (a) and Y_1 and Y_2 represent a nitrogen atom, characterized in that a compound of formula (V):



(V)

is reacted with a compound of formula (III) as defined in claim 8, the nitro group of the product of formula (VI) thus obtained:



(VI)

is reduced, the product of formula (VII) thus obtained:



(VII)

is treated with a carbonylation agent, the product of formula (I) thus obtained is isolated and, optionally, is converted into one of its salts or solvates.

11. The process as claimed in claim 10, characterized in that the carbonylation agent is chosen from carbonyldiimidazole and phosgene.

12. A pharmaceutical composition comprising at least one compound of claim 1 as active principle.

13. Use of the compound as claimed in claim 1 for the preparation of medicaments indicated in irritable bowel syndrome, or with a modulating effect on intestinal motility, lipolytic agent, antiobesity agent, antidiabetic, psychotropic, antiglaucoma agent, cicatrizant or antidepressant, or as tocolytics for preventing or delaying premature labor or for the treatment and/or prophylaxis of dysmenorrhea.